4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer
Dr. Lee brings over 20 years of biotechnology industry and Wall Street experience
Skillman, NJ – March 4, 2024 – 4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced the appointment of Kimberly Lee, D.O. as Chief Business Officer and member of the executive management team. Dr. Lee has over 20 years of biotechnology industry and Wall Street experience with expertise in financial and corporate strategy across a broad range of therapeutic areas including CNS, oncology, nephrology, pain and metabolic and rare diseases.
“We are excited to welcome Kim to the team to maximize the potential of our pipeline and to drive strategic growth,” said Dr. Pablo Lapuerta, Chief Executive Officer and Co-founder of 4M Therapeutics. “Her experience will be instrumental as we enter the next phase of the company's life cycle.”
Over the past year, Dr. Lee collaborated with 4M Therapeutics as a strategic advisor, providing tactical input and support to the Company’s management team. Prior to that, she held the role of Chief Corporate Affairs Officer at Taysha Gene Therapies. Prior to joining Taysha, she served as Head of Corporate Strategy and Investor Relations at Lexicon Pharmaceuticals, Inc., and Vice President of Corporate Strategy, Corporate Communications, and Investor Relations at Raptor Pharmaceuticals through its acquisition by Horizon Pharma. Preceding her corporate roles, Kim served as a Managing Director and Senior Equity Research Analyst covering the biotechnology sector at Janney Montgomery Scott and ThinkEquity. She also held equity research roles at Wedbush Securities and Jefferies after beginning her career on Wall Street at Stephens. Dr. Lee received her B.S. in Biological Sciences from Stanford University and her medical degree from Kirksville College of Osteopathic Medicine. She is a licensed physician in California and has published in several peer-reviewed journals.
“During my time as an advisor, I was incredibly impressed by the progress made at 4M Therapeutics in the development of more targeted and safer alternatives to lithium and atypical antipsychotics, and the potential for differentiated value creation and am thrilled to now be joining the company in this new role,” said Dr. Lee. “I look forward to working more closely with the team and its world-leading group of scientific innovators to position the company for long-term success and to ultimately bring transformative treatment options to the significant patient population suffering from mental health disorders that are underserved by the current standard of care, beginning with bipolar mania.”
About 4M Therapeutics Inc.
4M Therapeutics Inc. (4MTx) is advancing treatments for neuropsychiatric and neurodegenerative conditions. The Company focuses on targets for a wide array of disorders and indications. 4MTx applies unique insights from its living human brain cell platform, which was developed through a collaborative effort between Harvard, MIT, and the University of Washington to identify and design more effective and safer therapeutics. The Company’s pipeline includes potential breakthrough treatments for bipolar mania, agitation in Alzheimer’s disease, neurodegeneration, and other CNS disorders. For more information, visit www.4mtx.net.
For investor and media inquiries, please contact:
Kimberly Lee, DO
Chief Business Officer